Farletuzumab in epithelial ovarian carcinoma

Area of Science:

• Gynecologic Oncology
• Immunotherapy
• Targeted Cancer Therapy

Background:

• Ovarian cancer is a leading cause of gynecologic cancer mortality.
• Recurrent ovarian cancer necessitates novel targeted therapies.
• Folate receptor alpha (FRalpha) is overexpressed in most epithelial ovarian cancers.

Purpose of the Study:

• To review preclinical and clinical data on farletuzumab (MORAb-003) for ovarian cancer.
• To evaluate farletuzumab as a targeted therapy for FRalpha-expressing ovarian cancers.

Main Methods:

• Review of preclinical studies (in vitro and in vivo xenografts).
• Analysis of Phase I and II clinical trials.
• Examination of toxicology in non-human primates.

Main Results:

• Preclinical studies demonstrated antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and tumor growth inhibition.
• Early clinical trials (Phase I/II) showed efficacy as a single agent and in combination therapy with minimal toxicity.
• Phase III trials are planned for platinum-sensitive and platinum-resistant recurrent ovarian cancer.

Conclusions:

• Folate receptor alpha (FRalpha) is a validated therapeutic target in ovarian cancer due to its overexpression and limited presence in normal tissues.
• Farletuzumab is a promising FRalpha-targeting antibody with demonstrated clinical efficacy in early-phase trials.
• Further development in Phase III trials is warranted for farletuzumab in recurrent ovarian cancer.